| Phase | Design | Target Population | Primary Endpoint | Expected Milestones | |-------|--------|-------------------|------------------|---------------------| | (dose‑finding, safety) | Open‑label, 3‑plus‑3 escalation → expansion cohorts | KRAS‑G12D+ solid tumors (pancreatic, colorectal, NSCLC) with RAF‑DimerScore ≥ 2 | ORR (RECIST v1.1) + safety | IND filing Q3 2024 → First patient in Q1 2025 | | Phase 2b (confirmatory) | Randomized, double‑blind, MEYD‑873 + standard chemo vs. chemo alone | Same as above | PFS, OS, and biomarker‑driven subgroup analysis | Topline data Q4 2026 | | Phase 3 (global pivotal) | Multi‑regional, double‑blind | KRAS‑G12D+/RAF‑high metastatic pancreatic adenocarcinoma (primary) and KRAS‑G12D+ NSCLC (secondary) | OS superiority | NDA submission Q2 2029 |
Given the information you've provided, I can offer a very generic template for a write-up: MEYD-873
Best for: Fans of slow-burn, emotionally driven MILF dramas and admirers of Yuri Honma’s acting. Not for: Viewers seeking wild plots, group scenes, or fast-paced action. | Phase | Design | Target Population |
Yuri Honma plays a married woman whose husband has grown cold and neglectful. Her husband’s best friend (a younger man) begins staying over due to circumstances. Initially, it's just awkward domestic tension, but soon his longing looks and her pent-up loneliness erupt into a secret, passionate affair. Yuri Honma plays a married woman whose husband
Patients meeting both criteria are the ideal candidates for MEYD‑873 therapy. Our companion diagnostic is already CE‑IVD approved and will be launched concurrently with the drug.